| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Expression and ActivationLaboratory of Metabolism (Y.Z., K.W.K., C.C., F.J.G.), National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892; and Institute of Pharmacology (J.R.I.), First Faculty of Medicine, Charles University, 128 00 Praha 2, Czech Republic
Address all correspondence and requests for reprints to: Frank J. Gonzalez, Laboratory of Metabolism, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892. E-mail: fjgonz{at}helix.nih.gov.
Peroxisome proliferator-activated receptor
(PPAR
) is a nuclear receptor with manifold effects on intermediary metabolism. To define a set of urinary biomarkers that could be used to determine the efficacy of PPAR
agonists, a metabolomic investigation was undertaken in wild-type and Ppar
-null mice fed for 2 wk either a regular diet or a diet containing the PPAR
ligand Wy-14,643 ([4-chloro-6-(2,3-xylidino)-2-pyrimidinylthio] acetic acid), and their urine was analyzed by ultra-performance liquid chromatography coupled with time-of-flight mass spectrometry. Principal components analysis of 6393 accurate mass positive ions revealed clustering as a single phenotype of the treated and untreated Ppar
(–/–) mice plus two additional discrete phenotypes for the treated and untreated Ppar
(+/+) mice. Biomarkers of PPAR
activation were identified from their accurate masses and confirmed by tandem mass spectrometry of authentic compounds. Biomarkers were quantitated from raw chromatographic data using appropriate calibration curves. PPAR
urinary biomarkers highly statistically significantly elevated by Wy-14,643 treatment included 11ß-hydroxy-3,20-dioxopregn-4-en-21-oic acid (>3700-fold), 11ß,20-dihydroxy-3-oxopregn-4-en-21-oic acid (50-fold), nicotinamide (>2-fold), nicotinamide 1-oxide (5-fold), 1-methylnicotinamide (1.5-fold), hippuric acid (2-fold), and 2,8-dihydroxyquinoline-ß-D-glucuronide (3-fold). PPAR
urinary biomarkers highly statistically significantly attenuated by Wy-14,643 treatment included xanthurenic acid (1.3-fold), hexanoylglycine (20-fold), phenylpropionylglycine (4-fold), and cinnamoylglycine (9-fold). These biomarkers arise from PPAR
effects on tryptophan, corticosterone, and fatty acid metabolism and on glucuronidation. This study underscores the power of mass spectrometry-based metabolomics combined with genetically modified mice in the definition of monogenic metabolic phenotypes.
NURSA Molecule Pages Link:
This article has been cited by other articles:
![]() |
A. Liu, A. D. Patterson, Z. Yang, X. Zhang, W. Liu, F. Qiu, H. Sun, K. W. Krausz, J. R. Idle, F. J. Gonzalez, et al. Fenofibrate Metabolism in the Cynomolgus Monkey using Ultraperformance Liquid Chromatography-Quadrupole Time-of-Flight Mass Spectrometry-Based Metabolomics Drug Metab. Dispos., June 1, 2009; 37(6): 1157 - 1163. [Abstract] [Full Text] [PDF] |
||||
![]() |
J.-Y. Cho, D. W. Kang, X. Ma, S.-H. Ahn, K. W. Krausz, H. Luecke, J. R. Idle, and F. J. Gonzalez Metabolomics reveals a novel vitamin E metabolite and attenuated vitamin E metabolism upon PXR activation J. Lipid Res., May 1, 2009; 50(5): 924 - 937. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. A. Kamleh, J. A. T. Dow, and D. G. Watson Applications of mass spectrometry in metabolomic studies of animal model and invertebrate systems Brief Funct Genomic Proteomic, January 1, 2009; 8(1): 28 - 48. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |